Page last updated: 2024-12-08
forosamine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
forosamine: from spiramycin; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 193532 |
| CHEBI ID | 32541 |
| SCHEMBL ID | 465861 |
| MeSH ID | M0059280 |
Synonyms (9)
| Synonym |
|---|
| forosamine |
| 18423-27-3 |
| CHEBI:32541 |
| 2,3,4,6-tetradeoxy-4-dimethylamino-d-erythro-hexose |
| (4s,5r)-4-(dimethylamino)-5-hydroxyhexanal |
| 4-dimethylamino-2,3,4,6-tetradeoxy-d-erythro-hexose |
| SCHEMBL465861 |
| DTXSID60171548 |
| Q27114982 |
Research Excerpts
Overview
d-Forosamine is a 4-N,N-(dimethylamino)-2,3,4,6-tetradeoxy-alpha-d-threo-hexopyranose found in spinosyn produced by Saccharopolyspora spinosa.
| Excerpt | Reference | Relevance |
|---|---|---|
| "d-Forosamine is a 4-N,N-(dimethylamino)-2,3,4,6-tetradeoxy-alpha-d-threo-hexopyranose found in spinosyn produced by Saccharopolyspora spinosa. " | ( Characterization of protein encoded by spnR from the spinosyn gene cluster of Saccharopolyspora spinosa: mechanistic implications for forosamine biosynthesis. Hong, L; Liu, HW; Zhao, Z, 2005) | 1.25 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " The 2'-deoxy analog (BCX-3040) was synthesized and its pharmacokinetic and pharmacodynamic properties compared with forodesine HCl." | ( Synthesis and pharmacokinetic and pharmacodynamic evaluation of the forodesine HCl analog BCX-3040. Kellogg, D; Kezar, HS; Kilpatrick, JM; Morris, PE; Phillips, D; Zhang, J, 2005) | 0.33 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " Animal models indicated that forodesine HCl would have low oral bioavailability in humans and it was initially developed as an intravenous formulation." | ( Synthesis and pharmacokinetic and pharmacodynamic evaluation of the forodesine HCl analog BCX-3040. Kellogg, D; Kezar, HS; Kilpatrick, JM; Morris, PE; Phillips, D; Zhang, J, 2005) | 0.33 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
| Class | Description |
|---|---|
| hexosamine | Any 6-carbon amino monosaccharide with at least one alcoholic hydroxy group replaced by an amino group. |
| tetradeoxyhexose derivative | A deoxyhexose derivative that is formally obtained from a tetradeoxyhexose. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (14)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 28.40
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (28.40) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (7.14%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (92.86%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||